Jiacheng Bi

2.5k total citations · 1 hit paper
30 papers, 1.9k citations indexed

About

Jiacheng Bi is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Jiacheng Bi has authored 30 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Immunology, 9 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Jiacheng Bi's work include Immune Cell Function and Interaction (23 papers), CAR-T cell therapy research (8 papers) and T-cell and B-cell Immunology (7 papers). Jiacheng Bi is often cited by papers focused on Immune Cell Function and Interaction (23 papers), CAR-T cell therapy research (8 papers) and T-cell and B-cell Immunology (7 papers). Jiacheng Bi collaborates with scholars based in China, United States and Hong Kong. Jiacheng Bi's co-authors include Zhigang Tian, Haiming Wei, Rui Sun, Yongyan Chen, Xiaodong Zheng, Wenyong Wu, Qing Zhang, Hua Wang, Hui Peng and Zhengguang Wang and has published in prestigious journals such as Nature Immunology, The Journal of Immunology and Hepatology.

In The Last Decade

Jiacheng Bi

29 papers receiving 1.8k citations

Hit Papers

Blockade of the checkpoint receptor TIGIT prevents NK cel... 2018 2026 2020 2023 2018 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiacheng Bi China 18 1.4k 976 304 113 106 30 1.9k
Nadia Guerra United Kingdom 22 1.7k 1.2× 868 0.9× 327 1.1× 98 0.9× 163 1.5× 32 2.2k
Ravikumar Muthuswamy United States 24 1.6k 1.1× 958 1.0× 458 1.5× 102 0.9× 129 1.2× 34 2.1k
Elena Shklovskaya Australia 21 1.1k 0.8× 529 0.5× 357 1.2× 120 1.1× 113 1.1× 33 1.5k
Mar Cabeza-Cabrerizo United Kingdom 8 1.7k 1.2× 921 0.9× 522 1.7× 107 0.9× 139 1.3× 9 2.3k
Paolo Carrega Italy 23 2.0k 1.4× 922 0.9× 300 1.0× 241 2.1× 151 1.4× 40 2.5k
Qingsheng Li United States 16 2.2k 1.5× 948 1.0× 527 1.7× 72 0.6× 157 1.5× 29 2.7k
Takayuki Ohkuri Japan 22 1.5k 1.0× 976 1.0× 583 1.9× 59 0.5× 75 0.7× 56 2.0k
Xin Yao China 14 1.1k 0.8× 1.3k 1.3× 342 1.1× 82 0.7× 51 0.5× 40 1.8k
Linhua Vatan United States 9 1.8k 1.3× 1.1k 1.1× 355 1.2× 55 0.5× 94 0.9× 10 2.3k
Lucas A. Horn United States 20 1.2k 0.8× 1.0k 1.0× 462 1.5× 89 0.8× 111 1.0× 27 1.9k

Countries citing papers authored by Jiacheng Bi

Since Specialization
Citations

This map shows the geographic impact of Jiacheng Bi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiacheng Bi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiacheng Bi more than expected).

Fields of papers citing papers by Jiacheng Bi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiacheng Bi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiacheng Bi. The network helps show where Jiacheng Bi may publish in the future.

Co-authorship network of co-authors of Jiacheng Bi

This figure shows the co-authorship network connecting the top 25 collaborators of Jiacheng Bi. A scholar is included among the top collaborators of Jiacheng Bi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiacheng Bi. Jiacheng Bi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huang, Yingying, Zhigang Tian, & Jiacheng Bi. (2024). Intracellular checkpoints for NK cell cancer immunotherapy. Frontiers of Medicine. 18(5). 763–777. 3 indexed citations
2.
Bi, Jiacheng, Chen Huang, Yingying Huang, et al.. (2023). TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells. Journal for ImmunoTherapy of Cancer. 11(2). e006002–e006002. 13 indexed citations
3.
Afolabi, Lukman O., Jiacheng Bi, Liang Chen, Xiaolu Yang, & Xiaochun Wan. (2023). Suppression of protein quality control system by TRIM30a sensitises tumour cells to NK cell‐mediated immune surveillance. Immunology. 171(1). 60–76. 1 indexed citations
4.
Bi, Jiacheng, Chen Huang, Chao Zhong, et al.. (2023). Checkpoint TIPE2 Limits the Helper Functions of NK Cells in Supporting Antitumor CD8+ T Cells. Advanced Science. 10(12). e2207499–e2207499. 14 indexed citations
5.
Liu, Yao, Jing Xiao, Jiacheng Bi, et al.. (2023). Review immune response of targeting CD39 in cancer. Biomarker Research. 11(1). 63–63. 29 indexed citations
6.
Zheng, Xiaohu, Yaqi Wu, Jiacheng Bi, et al.. (2022). The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cellular and Molecular Immunology. 19(2). 192–209. 119 indexed citations
7.
Bi, Jiacheng. (2022). NK cell dysfunction in patients with COVID-19. Cellular and Molecular Immunology. 19(2). 127–129. 32 indexed citations
8.
Afolabi, Lukman O., Jiacheng Bi, Liang Chen, & Xiaochun Wan. (2021). A natural product, Piperlongumine (PL), increases tumor cells sensitivity to NK cell killing. International Immunopharmacology. 96. 107658–107658. 17 indexed citations
9.
Yang, Shuxin, Wenjuan Zhao, Meiling Jin, et al.. (2021). Tumor Temporal Proteome Profiling Reveals the Immunological Triple Offensive Induced by Synthetic Anti-Cancer Salmonella. Frontiers in Immunology. 12. 712936–712936. 9 indexed citations
10.
Afolabi, Lukman O., Jiacheng Bi, Xuguang Li, et al.. (2021). Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat. Frontiers in Immunology. 12. 701671–701671. 24 indexed citations
11.
Huang, Chen & Jiacheng Bi. (2021). Expression Regulation and Function of T-Bet in NK Cells. Frontiers in Immunology. 12. 761920–761920. 38 indexed citations
12.
Lu, Zhen, et al.. (2021). Exogenous oxidative stress suppresses IL-33 -driven proliferation programming in group 2 innate lymphoid cells. International Immunopharmacology. 95. 107541–107541. 3 indexed citations
13.
Lu, Zhen, Jiacheng Bi, & Xiaochun Wan. (2020). Artemisinin sensitizes tumor cells to NK cell-mediated cytolysis. Biochemical and Biophysical Research Communications. 524(2). 418–423. 18 indexed citations
14.
Bi, Jiacheng & Xuefu Wang. (2020). Molecular Regulation of NK Cell Maturation. Frontiers in Immunology. 11. 1945–1945. 44 indexed citations
15.
Bi, Jiacheng & Zhigang Tian. (2019). NK Cell Dysfunction and Checkpoint Immunotherapy. Frontiers in Immunology. 10. 1999–1999. 114 indexed citations
16.
17.
Zhang, Qing, Jiacheng Bi, Xiaodong Zheng, et al.. (2018). Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nature Immunology. 19(7). 723–732. 813 indexed citations breakdown →
18.
Zhang, Lijuan, Bin Xi, Fan Yang, et al.. (2015). Automatic recognition of cardiac arrhythmias based on the geometric patterns of Poincaré plots. Physiological Measurement. 36(2). 283–301. 23 indexed citations
19.
Bi, Jiacheng, Xiaodong Zheng, Yongyan Chen, et al.. (2014). TIGIT safeguards liver regeneration through regulating natural killer cell-hepatocyte crosstalk. Hepatology. 60(4). 1389–1398. 63 indexed citations
20.
Bi, Jiacheng, Qing Zhang, Lei Xiong, et al.. (2013). T-Cell Ig and ITIM Domain Regulates Natural Killer Cell Activation in Murine Acute Viral Hepatitis. Hepatology. 59(5). 1715–1725. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026